1. American Cancer Society. Cancer Treatment & Survivorship Facts & Figures 2019-2021. www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-treatment-and-survivorship-facts-and-figures/cancer-treatment-and-survivorship-facts-and-figures-2019-2021.pdf . Accessed September 4, 2019.
2. Stein KD, Syrjala KL, Andrykowski MA. Physical and psychological long-term and late effects of cancer. Cancer . 2008;112(11 suppl):2577-2592.
3. National Comprehensive Cancer Network. NCCN Guidelines Version 2. 2019. Palliative Care. www.nccn.org/professionals/physician_gls/pdf/palliative.pdf . (Must register an account for access. ) Accessed September 4, 2019.
4. American Cancer Society. New CoC accreditation standards gain strong support. www.facs.org/media/press-releases/2011/coc-standards0811 . Accessed September 11, 2019.
5. Lupu D; American Academy of Hospice and Palliative Medicine Workforce Task Force. Estimate of current hospice and palliative medicine physician workforce shortage. J Pain Symptom Manage . 2010;40:899-911.
6. Lupu D, Quigley L, Mehfoud N, et al. The growing demand for hospice and palliative medicine physicians: will the supply keep up? J Pain Symptom Manage . 2018;55:1216-1223.
7. Rabow MW, Dahlin C, Calton B, et al. New frontiers in outpatient palliative care for patients with cancer. Cancer Control . 2015;22:465-474.
8. Haun MW, Estel S, Rü cker G, et al. Early palliative care for adults with advanced cancer. Cochrane Database of Syst Rev . 2017:CD01129.
9. Buss MK, Rock LK, McCarthy EP. Understanding palliative care and hospice: a review for primary care providers. Mayo Clin Proc . 2017;92:280-286.
10. Hui D. Definition of supportive care: does the semantic matter? Curr Opin Oncol . 2014;26:372-379.
11. Simmons CPL, McMillan DC, McWilliams K, et al. Prognostic tools in patients with advanced cancer: a systematic review. J Pain Symptom Manage . 2017;53:962-970.
12. Lakin JR, Robinson MG, Bernacki RE, et al. Estimating 1-year mortality for high-risk primary care patients using the “surprise” question. JAMA Int Med . 2016;176:1863-1865.
13. Walczak A, Henselmans I, Tattersall MH, et al. A qualitative analysis of responses to a question prompt list and prognosis and end-of-life care discussion prompts delivered in a communication support program. Psychoonchology . 2015;24:287-293.
14. Yamaguchi T, Maeda I, Hatano Y, et al. Effects of end-of-life discussions on the mental health of bereaved family members and quality of patient death and care. J Pain Symptom Manage . 2017;54:17-26.
15. Wright AA, Zhang B, Ray A, et al. Associations between end-of-life discussions, patient mental health, medical care near death, caregiver bereavement adjustment. JAMA . 2008;300:1665-1673.
16. Teunissen SC, Wesker W, Kruitwagen C, et al. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage . 2007;34:94-104.
17. Gao W, Bennett MI, Stark D, et al. Psychological distress in cancer from survivorship to end of life: prevalence, associated factors and clinical implications. Eur J Cancer . 2010;46:2036-2044.
18. Scott IA, Gray LC, Martin JH, et al. Deciding when to stop: towards evidence-based deprescribing of drugs in older populations. Evid Based Med . 2013;18:121-124.
19. Gramling R, Fiscella K, Xing G, et al. Determinants of patient-oncologist prognostic discordance in advanced cancer. JAMA Oncol . 2016;2:1421-1426.
20. Epstein AS, Prigerson HG, O’Reilly EM, et al. Discussions of life expectancy and changes in illness understanding in patients with advanced cancer. J Clin Oncol . 2016;34:2398-2403.
21. Weeks JC, Cook EF, O’Day SJ, et al. Relationship between cancer patients’ predictions of prognosis and their treatment preferences. JAMA . 1998;279:1709-1714.
22. Myers J. Improving the quality of end-of-life discussions. Curr Opin Support Palliat Care . 2015;9:72-76.
23. Corli O, Floriani I, Roberto A, et al. Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV ‘real life’ trial on the variability of response to opioids. Ann Oncolog . 2016;27:1107-1115.
24. National Hospice and Palliative Care Organization. NHPCO Facts and Figures. 2018. www.nhpco.org/wp-content/uploads/2019/07/2018_NHPCO_Facts_Figures.pdf . Accessed September 24, 2019.
25. Meier EA, Gallegos JV, Thomas LP, et al. Defining a good death (successful dying): literature review and a call for research and public dialogue. Am J Geriatr Psychiatry . 2016;24:261-271.
26. Morden NE, Chang CH, Jacobson JO, et al. End-of-life care for Medicare beneficiaries with cancer is highly intensive overall and varies widely. Health Aff (Millwood) . 2012;31:786-796.
27. Centers for Medicare & Medicaid Services. Medicare Hospice Benefit Facts. www.cgsmedicare.com/hhh/education/materials/pdf/Medicare_Hospice_Benefit_Facts.pdf . Accessed September 11, 2019.
28. Centers for Medicare & Medicaid Services. Medicare Hospice Benefits. www.medicare.gov/pubs/pdf/02154-medicare-hospice-benefits.pdf . Accessed September 11, 2019.
29. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol . 2007;18:1437-1449.
30. Greco MT, Roberto A, Corli O, et al. Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer. J Clin Oncol . 2014;32:4149-4154.
31. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain — United States, 2016. MMWR Recomm Rep . 2016;65:1-49.
32. Davis MP, Mehta Z. Opioids and chronic pain: where is the balance? Curr Oncol Rep . 2016;18:71.
33. Leppert W, Zajaczkowska R, Wordliczek J, et al. Pathophysiology and clinical characteristics of pain in most common locations in cancer patients. J Physiol Pharmacol . 2016;67:787-799.
34. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol . 2015;14:162-173.
35. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA . 2015;313:2456-2473.
36. Jones JA, Lutz ST, Chow E. et al. Palliative radiotherapy at the end of life: a critical review. CA Cancer J Clin . 2014;64:296-310.
37. Prigerson HG, Bao Y, Shah MA, et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol . 2015;1:778-784.
38. Kongsgaard U, Kaasa S, Dale O, et al. Palliative treatment of cancer-related pain. 2005. www.ncbi.nlm.nih.gov/books/NBK464794/ . Accessed September 24, 2019.
39. Sathornviriyapong A, Nagaviroj K, Anothaisintawee T. The association between different opioid doses and the survival of advanced cancer patients receiving palliative care. BMC Palliat Care . 2016;15:95.
40. Steindal SA, Bredal IS. Sø rbye LW, et al. Pain control at the end of life: a comparative study of hospitalized cancer and noncancer patients. Scand J Caring Sci . 2011;25:771-779.
41. Maltoni M, Setola E. Palliative sedation in patients with cancer. Cancer Control . 2015;22:433-441.
42. Cooper C, Burden ST, Cheng H, et al. Understanding and managing cancer-related weight loss and anorexia: insights from a systematic review of qualitative research. J Cachexia Sarcopenia Muscle . 2015;6:99-111.
43. Ruiz Garcia V, LÓpez-Briz E, Carbonell Sanchis R, et al. Megesterol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev . 2013;28:CD004310.
44. Chey WD, Webster L, Sostek M, et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med . 2014;370:2387-2396.
45. Poulsen JL, Nilsson M, Brock C, et al. The impact of opioid treatment on regional gastrointestinal transit. J Neurogastroenterol Motil . 2016;22:282-291.
46. Pergolizzi JV, Raffa RB, Pappagallo M, et al. Peripherally acting μ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy. Patient Prefer Adherence . 2017;11:107-119.
47. Walsh D, Davis M, Ripamonti C, et al. 2016 updated MASCC/ESMO consensus recommendations: management of nausea and vomiting in advanced cancer. Support Care Cancer . 2017;25:333-340.
48. Mü cke M, Mochamat, Cuhls H, et al. Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev . 2015(5):CD006788.
49. Escalante CP, Meyers C, Reuben JM, et al. A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. Cancer J . 2014;20:8-14.
50. Hovey E, de Souza P, Marx G, et al. Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy. Support Care Cancer . 2014;22:1233-1242.
51. Hosker CM, Bennett MI. Delirium and agitation at the end of life. BMJ . 2016;353:i3085.
52. Mercantonio ER, Flacker JM, Wright RJ, et al. Reducing delirium after hip fracture: a randomized trial. J Am Geriatr Soc . 2001;49:516-522.
53. Casarett DJ, Inouye SK. Diagnosis and management of delirium near the end of life. Ann Int Med . 2001;135:32-40.
54. Breitbart W, Alici Y. Agitation and delirium at the end of life: “We couldn’t manage him." JAMA . 2008;300:2898-2910.
55. Candy B, Jackson KC, Jones L, et al. Drug therapy for delirium in terminally ill patients. Cochrane Database Syst Rev . 2012;11:CD004770.
56. Bascom PB, Bordley JL, Lawton AJ. High-dose neuroleptics and neuroleptic rotation for agitated delirium near the end of life. Am J Hosp Palliat Med . 2014;31:808-811.
57. Maltoni M, Scarpi E, Rosati M, et al. Palliative sedation in end-of-life care and survival: a systematic review. J Clin Oncol . 2012;30:1378-1383.
58. Albert RH. End-of-life care: managing common symptoms. Am Fam Physician . 2017;95:356-361.
59. Arenella C. Artificial nutrition and hydration at the end of life: beneficial or harmful? https://americanhospice.org/caregiving/artificial-nutrition-and-hydration-at-the-end-of-life-beneficial-or-harmful/ Accessed September 11, 2019.
60. Booth S, Moffat C, Burkin J, et al. Nonpharmacological interventions for breathlessness. Curr Opinion Support Pall Care . 2011;5:77-86.
61. Barnes H, McDonald J, Smallwood N, et al. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness. Cochrane Database Syst Rev . 2016(3)CD011008.
62. Lim RB. End-of-life care in patients with advanced lung cancer. Ther Adv Resp Dis . 2016;10:455-467.
63. Kreher M. Symptom control at the end of life. Med Clin North Am . 2016;100:1111-1122.
64. Baralatei FT, Ackerman RJ. Care of patients at the end of life: management of nonpain symptoms. FP Essent . 2016;447:18-24.
65. Protus BM, Grauer PA, Kimbrel JM. Evaluation of atropine 1% ophthalmic solution administered sublingual for the management of terminal respiratory secretions. Am J Hosp Palliat Med . 2013;30:388-392.
